A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

A study comparing men and women suggests much of the association arises from genetic propensity to both conditions.

In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Fitness doesn’t make people immune to atherosclerosis, but what to do with the finding in asymptomatic patients is uncertain.

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

An app-based program failed to boost function for most at 3 months, but positive signs were seen in women and after CABG.

Greater transparency, monitoring, and regulatory oversight are needed around these transactions, a researcher says.

The aim is to make it easier for consumers to determine how much saturated fat, sodium, and added sugar are inside.

Two new trials saw no impact of thrombolytics in reducing disability at 90 days, but some positive signals offer hope.

The two-tiered classification focuses on preclinical and clinical stages of disease, and should help inform treatment ...